skip to main content

NSCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerNSCLCSCE Medical Oncology

A fit patient has a completely resected pT2aN0 lung adenocarcinoma with an EGFR exon 19 deletion and completes platinum-based adjuvant chemotherapy. Which additional treatment and maximum duration match current NICE guidance?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Adjuvant osimertinib continued for a maximum of 3 years after chemotherapy

NICE TA1043 recommends adjuvant osimertinib after complete resection for stage 1b–3a NSCLC with EGFR exon 19 deletion or L858R mutation. It is stopped at 3 years, recurrence or unacceptable toxicity. Node-negative stage 1b disease is included; pembrolizumab is not substituted for an EGFR-directed adjuvant therapy, and gefitinib is not the technology-appraised option.

Reference: NICE TA1043 osimertinib after complete resection of EGFR mutation-positive NSCLC (Published February 2025): https://www.nice.org.uk/guidance/ta1043/chapter/1-Recommendation